+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acinetobacter Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Xacduro, Polymyxins, Cephalosporins, Carbapenems), By Route Of Administration (Oral, Parenteral), By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • April 2024
  • Region: Global
  • Grand View Research
  • ID: 5967396
Description Jump to:

Acinetobacter Pneumonia Therapeutics Market Growth & Trends

The global acinetobacter pneumonia therapeutics market size is expected to reach USD 470.96 million by 2030, registering a CAGR of 6.70% from 2024 to 2030. Several factors are responsible for driving market growth including a high incidence of acinetobacter infections, rising antibiotic resistance, extensive R&D, and favorable government initiatives & funding, and rising drug resistance. Acinetobacter baumannii is a major pathogen responsible for causing hospital-acquired infections in hospitalized patients. The pathogen causes ventilator-associated pneumonia and bloodstream infection. This strain of microorganisms has been reported to be multidrug-resistant and can spread extremely fast.

The treatment of this microorganism can be challenging and is hampered due to the multidrug resistance of the Acinetobacter baumannii. Combination therapy is the most widely used treatment for these kinds of infections. The first line of treatment for acinetobacter pneumonia includes drug classes, such as β-lactam antibiotics, cephalosporins, carbapenem, fluoroquinolone, sulbactam, and sulfonamide. The therapeutics are used in monotherapy or as part of combination therapy depending on the severity of illness. In case the first-line treatment is not effective, second-line antibiotics are administered, which include drug classes, such as aminoglycoside, polymyxins, tetracycline, and glycylcycline. These drugs are considered second-line due to their adverse effects.

Acinetobacter Pneumonia Therapeutics Market Report Highlights

  • The cephalosporins drug class segment accounted for the largest revenue share in 2023. Ceftazidime is used as a first-line treatment; cefiderocol is used as second-linene treatment for the disease
  • In addition, the newly launched Xacduro under the sulbactam segment is expected to grow at a significant CAGR during the forecast period
  • Based on the route of administration, the parenteral segment accounted for the largest revenue share in 2023. The rapid and direct delivery of antibiotics via the IV route ensures rapid absorption and efficacy and makes it the preferred method for treating severe infections
  • Xacduro (sulbactam for injection; durlobactam for injection), polymyxins (colistin), carbapenems, and aminoglycosides are some of the drugs administered parenterally for the treatment of acinetobacter pneumonia
  • In 2023, North America dominated with a share of 37.31% owing to the advanced healthcare infrastructure, high awareness levels, and extensive research activities for clinical trials
  • The region has a high prevalence of acinetobacter pneumonia along with high awareness about disease diagnosis and treatment

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Route of Administration
1.3. Regional scope
1.4. Estimates and forecasts timeline
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased database
1.6.2. Internal Database
1.6.3. Secondary sources
1.6.4. Primary research
1.6.5. Details of primary research
1.6.5.1. Data for primary interviews in North America
1.6.5.2. Data for primary interviews in Europe
1.6.5.3. Data for primary interviews in Asia Pacific
1.6.5.4. Data for primary interviews in Latin America
1.6.5.5. Data for Primary interviews in MEA
1.7. Information or Data Analysis
1.7.1. Data analysis models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity flow analysis (Model 1)
1.9.2. Approach 1: Commodity flow approach
1.9.3. Volume price analysis (Model 2)
1.9.4. Approach 2: Volume price analysis
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Route of administration outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Acinetobacter Pneumonia Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing incidence of Acinetobacter infections
3.2.1.2. Increasing prevalence of antibiotic resistance
3.2.1.3. Increasing research & development and fundings
3.2.2. Market restraint analysis
3.2.2.1. Side effects and adverse reactions
3.2.2.2. High cost of drug development
3.3. Acinetobacter Pneumonia Therapeutics Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
Chapter 4. Acinetobacter Pneumonia Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Segment Dashboard
4.2. Global Acinetobacter Pneumonia Therapeutics Market: Drug Class Movement Analysis
4.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Cephalosporins
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Fluoroquinolone
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Glycylcycline
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Carbapenem
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. ß-Lactam antibiotics
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Sulbactam
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Aminoglycoside
4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Polymyxins
4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.12. Tetracycline
4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.13. Sulfonamide
4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.14. Other
4.14.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Acinetobacter Pneumonia Therapeutics Market: Route of Administration Estimates & Trend Analysis
5.1. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Segment Dashboard
5.2. Global Acinetobacter Pneumonia Therapeutics Market: Route of Administration Movement Analysis
5.3. Global Acinetobacter Pneumonia Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
5.4. Parenteral
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Oral
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Acinetobacter Pneumonia Therapeutics Market: Regional Estimates & Trend Analysis by
6.1. Regional Market Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework/ reimbursement structure
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework/ reimbursement structure
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework/ reimbursement structure
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework/ reimbursement structure
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework/ reimbursement structure
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. China
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. India
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Australia
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. South Korea
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Mexico
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. Argentina
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. UAE
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Kuwait
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. Pfizer Inc.
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Merck & Co., Inc.
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. GlaxoSmithKline plc (GSK)
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. AstraZeneca plc
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Novartis AG
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Johnson & Johnson
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Sanofi S.A.
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Bayer AG
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Basilea Pharmaceutica
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
List of Tables
Table 1 List of key distributors and channel partners
Table 2 List of key emerging companies’/technology disruptors/innovators
Table 3 North America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
Table 4 North America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 5 North America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 U.S. Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 7 U.S. Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 8 Canada Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 9 Canada Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 10 Europe Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
Table 11 Europe Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 12 Europe Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 13 Germany Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 14 Germany Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 15 UK Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 16 UK Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 17 France Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 18 France Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 19 Italy Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 20 Italy Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
Table 21 Spain Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 22 Spain Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 23 Denmark Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 24 Denmark Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 25 Sweden Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 26 Sweden Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 27 Norway Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 28 Norway Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 29 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
Table 30 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 31 Asia Pacific Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 32 Japan Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 33 Japan Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 China Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 35 China Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 36 India Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 37 India Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 38 Australia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 39 Australia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 40 South Korea Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 41 South Korea Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 42 Thailand Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 43 Thailand Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 44 Latin America Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
Table 45 Latin America Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 46 Latin America Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million
Table 47 Brazil Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 48 Brazil Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 49 Mexico Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 50 Mexico Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 51 Argentina Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 52 Argentina Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 53 MEA Acinetobacter Pneumonia Therapeutics Market, by country, 2018 - 2030 (USD Million)
Table 54 MEA Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 55 MEA Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 56 South Africa Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 57 South Africa Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 60 UAE Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 61 UAE Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 62 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Drug class, 2018 - 2030 (USD Million)
Table 63 Kuwait Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Acinetobacter pneumonia therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Acinetobacter pneumonia therapeutics market snapshot (2023)
Fig. 9 Acinetobacter pneumonia therapeutics market: Segment snapshot (2023)
Fig. 10 Competitive Insights (2023)
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Acinetobacter Pneumonia Therapeutics Market driver impact
Fig. 15 Acinetobacter Pneumonia Therapeutics Market restraint impact
Fig. 16 Porter’s Five Forces Analysis
Fig. 17 SWOT Analysis, By Factor (Political & legal Economic and technological)
Fig. 18 Strategic alliance analysis
Fig. 19 Recent developments & impact analysis, by key market participants
Fig. 20 Key company market share analysis, 2023
Fig. 21 Company market position analysis
Fig. 22 Definition and scope, by drug class
Fig. 23 Drug class market share analysis, 2023 & 2030
Fig. 24 Segment dashboard
Fig. 25 Global Acinetobacter Pneumonia Therapeutics Market, by drug class, 2018 - 2030 (USD Million)
Fig. 26 Cephalosporins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 27 Nonsteroidal Anti-inflammatory Drugs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 28 Naproxen market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 29 Fluoroquinolone market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 30 Glycylcycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 31 Carbapenem market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 32 ß-Lactam antibiotics market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 33 Sulbactam market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 34 Aminoglycoside market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 35 Polymyxins market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 36 Other NSAIDs market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 37 Tetracycline market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 38 Sulfonamide market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 39 Others market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 40 Definition and scope, by Route of Administration
Fig. 41 Anatomy market share analysis, 2023 & 2030
Fig. 42 Segment dashboard
Fig. 43 Global Acinetobacter Pneumonia Therapeutics Market, by Route of Administration, 2018 - 2030 (USD Million)
Fig. 44 Parenteral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 45 Oral market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 46 Other route market size & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 47 North America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 48 U.S. market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 49 Canada market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 50 Europe market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 51 UK market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 52 Germany market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 53 Spain market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 54 France market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 55 Italy market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 56 Sweden market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 57 Denmark market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 58 Norway market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 59 Asia Pacific market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 60 China market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 61 Japan market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 62 India market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 63 Australia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 64 South Korea market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 65 Thailand market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 66 Latin America market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 67 Brazil market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 68 Mexico market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 69 Argentina market size, & forecasts and trend analysis, 2018 to 2030 (USD Million))
Fig. 70 Middle East and Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 71 South Africa market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 72 Saudi Arabia market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 73 UAE market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)
Fig. 74 Kuwait market size, & forecasts and trend analysis, 2018 to 2030 (USD Million)

Companies Mentioned

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc (GSK)
  • AstraZeneca plc
  • Novartis AG
  • Johnson & Johnson
  • Sanofi S.A.
  • Bayer AG
  • Basilea Pharmaceutica

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedApril 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 300.81 Million
Forecasted Market Value ( USD ) by 2030 $ 470.96 Million
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast to 2024-2034 - Product Image

Acinetobacter Pneumonia Therapeutics Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Pneumonia Therapeutics Market by Drug Class, Pneumonia Type, Age Group, Distribution Channel - Global Forecast 2025-2030 - Product Image

Pneumonia Therapeutics Market by Drug Class, Pneumonia Type, Age Group, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Pneumonia Therapeutics - Global Strategic Business Report - Product Image

Pneumonia Therapeutics - Global Strategic Business Report

  • Report
  • 100 Pages
  • Global
From
Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Bacterial Pneumonia Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Bacterial Pneumonia Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 87 Pages
  • Global
From

About the Acinetobacter Pneumonia Drugs Market

The Acinetobacter pneumonia drugs market is a specialized segment within the broader respiratory drugs market, focused on the treatment of pneumonia caused by the Acinetobacter species of bacteria. These bacteria are known for their strong resistance to antibiotics and are recognized as a cause of severe lung infections, particularly in healthcare settings. The market comprises various antimicrobial agents, including carbapenems, aminoglycosides, sulbactam, and tigecycline, among others. These drugs are often used in combination to combat the multi-drug resistant nature of Acinetobacter infections. Treatment approaches can vary depending on the susceptibility profile of the bacteria and the severity of the infection. The development of effective treatment strategies is challenging due to the organism's ability to rapidly develop resistance to existing antibiotics. Thus, the market is characterized by a need for continuous research and development of new therapeutic options. Several companies engage in the production and development of therapies for Acinetobacter pneumonia. Major players in the market include Pfizer Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, and Bayer AG. These companies are involved in the manufacturing of antibiotics and are actively investing in research to create more effective treatments for resistant strains of Acinetobacter. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.